aTyr Pharma to present preclinical research on ATYR0101 at symposia on Firbosis

aTyr Pharma (ATYR) announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. ATYR0101 is a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase, DARS, that binds to latent transforming growth factor beta binding protein 1, LTBP-1, to induce myofibroblast apoptosis. “We are excited by these findings that further demonstrate the way in which ATYR0101 binds a known fibrosis target with pronounced effects in preclinical models of lung and renal fibrosis,” said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “These findings suggest that ATYR0101 has the potential to be a next generation anti-fibrotic for lung and kidney fibrosis with a differentiated mechanism of action compared to current standard of care that could potentially treat advanced fibrotic conditions.”